ESO-话题@MedSci

#ESO#

55篇内容 | 2096人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1493296, encodeId=4a0f149329628, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=J Endod：Resolvin E1通过Chemerin受体23抑制牙髓成纤维细胞活性改善牙髓炎, objectType=article, longId=177311, objectId=a61d1e731124, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a61d1e731124, replyNumber=0, likeNumber=66, createdTime=2019-08-10, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a61d1e731124, moduleTitle=J Endod：Resolvin E1通过Chemerin受体23抑制牙髓成纤维细胞活性改善牙髓炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a61d1e731124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493295, encodeId=e2c6149329594, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=NEJM：volanesorsen治疗乳糜微粒血症的关键研究结果, objectType=article, longId=177302, objectId=a8a61e7302b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8a61e7302b0, replyNumber=0, likeNumber=56, createdTime=2019-08-10, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8a61e7302b0, moduleTitle=NEJM：volanesorsen治疗乳糜微粒血症的关键研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8a61e7302b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493294, encodeId=fdd21493294d1, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=Blood：Resolvin D4 (RvD4)可减轻病理性血栓形成, objectType=article, longId=175630, objectId=fe3f1e563043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe3f1e563043, replyNumber=0, likeNumber=57, createdTime=2019-07-18, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe3f1e563043, moduleTitle=Blood：Resolvin D4 (RvD4)可减轻病理性血栓形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe3f1e563043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493293, encodeId=fc6814932936b, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=ESOC2019丨混合性颅内出血的致残风险更高, objectType=article, longId=168096, objectId=9dd0168096b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dd0168096b2, replyNumber=0, likeNumber=79, createdTime=2019-06-12, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dd0168096b2, moduleTitle=ESOC2019丨混合性颅内出血的致残风险更高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dd0168096b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493292, encodeId=b1a61493292e6, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=抗凝治疗脑出血怎么办？ESO 指南来支招, objectType=article, longId=166712, objectId=24a9166e12bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24a9166e12bb, replyNumber=0, likeNumber=75, createdTime=2019-05-25, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24a9166e12bb, moduleTitle=抗凝治疗脑出血怎么办？ESO 指南来支招, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24a9166e12bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493291, encodeId=42791493291af, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=2019 ESO指南：卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗, objectType=article, longId=165554, objectId=60da165554b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60da165554b1, replyNumber=0, likeNumber=61, createdTime=2019-05-08, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60da165554b1, moduleTitle=2019 ESO指南：卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60da165554b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493290, encodeId=905d149329077, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=2019 ESO/ESMINT指南：急性缺血性卒中机械血栓清除术, objectType=article, longId=162168, objectId=06cc162168e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06cc162168e9, replyNumber=0, likeNumber=45, createdTime=2019-03-13, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06cc162168e9, moduleTitle=2019 ESO/ESMINT指南：急性缺血性卒中机械血栓清除术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06cc162168e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493289, encodeId=7ff0149328950, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=【CSH重磅发布】伊布替尼一线治疗CLL研究RESONATE-2发布55个月随访结果, objectType=article, longId=152263, objectId=452d1522636d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=452d1522636d, replyNumber=0, likeNumber=57, createdTime=2018-10-31, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=452d1522636d, moduleTitle=【CSH重磅发布】伊布替尼一线治疗CLL研究RESONATE-2发布55个月随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=452d1522636d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493288, encodeId=26931493288db, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=Lancet：Resolute Onyx支架，效果和安全性不次于Orsiro药物洗脱支架的新型血管支架, objectType=article, longId=149448, objectId=eb75149448f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb75149448f0, replyNumber=0, likeNumber=70, createdTime=2018-09-25, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb75149448f0, moduleTitle=Lancet：Resolute Onyx支架，效果和安全性不次于Orsiro药物洗脱支架的新型血管支架, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb75149448f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493287, encodeId=f60f149328e5b, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=ESO-ESMO晚期乳腺癌国际共识指南更新了！看看不同类型乳腺癌怎么治？, objectType=article, longId=145577, objectId=0f461455e705, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f461455e705, replyNumber=0, likeNumber=75, createdTime=2018-08-02, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f461455e705, moduleTitle=ESO-ESMO晚期乳腺癌国际共识指南更新了！看看不同类型乳腺癌怎么治？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f461455e705)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493286, encodeId=3aad14932869f, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=Sci Rep：给药途径对阴道生殖模型中mesoangioblasts干细胞命运的影响研究, objectType=article, longId=144559, objectId=bcaf14455944, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcaf14455944, replyNumber=0, likeNumber=54, createdTime=2018-07-18, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcaf14455944, moduleTitle=Sci Rep：给药途径对阴道生殖模型中mesoangioblasts干细胞命运的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcaf14455944)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493285, encodeId=af56149328524, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=Hepatology：调节肠道胆汁酸/farnesoid X受体/成纤维细胞生长因子15轴，改善小鼠酒精性肝病, objectType=article, longId=141919, objectId=6633141919d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6633141919d8, replyNumber=0, likeNumber=104, createdTime=2018-06-30, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6633141919d8, moduleTitle=Hepatology：调节肠道胆汁酸/farnesoid X受体/成纤维细胞生长因子15轴，改善小鼠酒精性肝病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6633141919d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493284, encodeId=fda0149328494, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=【2018年EHA抢鲜报道】伊布替尼在CLL / SLL患者中的一线治疗：RESONATE-2研究的4年经验, objectType=article, longId=140718, objectId=caa0140e18ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=caa0140e18ef, replyNumber=0, likeNumber=44, createdTime=2018-06-15, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=caa0140e18ef, moduleTitle=【2018年EHA抢鲜报道】伊布替尼在CLL / SLL患者中的一线治疗：RESONATE-2研究的4年经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=caa0140e18ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493283, encodeId=cb90149328389, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=罗氏在“多重困难”后终止了olesoxime的开发, objectType=article, longId=139781, objectId=00ea139e81e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00ea139e81e8, replyNumber=0, likeNumber=54, createdTime=2018-06-03, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00ea139e81e8, moduleTitle=罗氏在“多重困难”后终止了olesoxime的开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00ea139e81e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493282, encodeId=0cd9149328270, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=CLIN CANCER RES：NY-ESO-1疫苗联合地西他滨可以诱导抗原特异性T淋巴细胞反应, objectType=article, longId=131478, objectId=aa8a1314e8be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa8a1314e8be, replyNumber=0, likeNumber=91, createdTime=2018-03-06, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa8a1314e8be, moduleTitle=CLIN CANCER RES：NY-ESO-1疫苗联合地西他滨可以诱导抗原特异性T淋巴细胞反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa8a1314e8be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493281, encodeId=ce1b149328130, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=EUR J Cancer：ipilimumab在NY-ESO-1阳性黑色素瘤患者中的作用, objectType=article, longId=131023, objectId=c06d1310231d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c06d1310231d, replyNumber=0, likeNumber=66, createdTime=2018-03-02, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c06d1310231d, moduleTitle=EUR J Cancer：ipilimumab在NY-ESO-1阳性黑色素瘤患者中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c06d1310231d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493280, encodeId=4e87149328060, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=2017 EAN/ESO共识声明：卒中院前管理, objectType=article, longId=123826, objectId=ef8c1238264e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef8c1238264e, replyNumber=0, likeNumber=66, createdTime=2017-12-19, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef8c1238264e, moduleTitle=2017 EAN/ESO共识声明：卒中院前管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef8c1238264e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493279, encodeId=5d6914932e936, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=Kidney int：中美洲肾病（Mesoamerican nephropathy）知多少？, objectType=article, longId=123438, objectId=b41c12343813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41c12343813, replyNumber=0, likeNumber=63, createdTime=2017-12-16, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41c12343813, moduleTitle=Kidney int：中美洲肾病（Mesoamerican nephropathy）知多少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41c12343813)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493278, encodeId=edc614932e82f, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, objectType=article, longId=123151, objectId=925712315133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925712315133, replyNumber=0, likeNumber=37, createdTime=2017-12-14, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925712315133, moduleTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925712315133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493277, encodeId=9e4b14932e769, content=<a href='/topic/show?id=4223e0260a' target=_blank style='color:#2F92EE;'>#ESO#</a>, objectTitle=TesoRx Pharma和ASKA Pharmaceutical扩大合作协议的领域和范围, objectType=article, longId=122351, objectId=0ae71223516e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ae71223516e, replyNumber=0, likeNumber=64, createdTime=2017-12-07, rootId=0, userName=hongbochen, userId=30f59021057, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ae71223516e, moduleTitle=TesoRx Pharma和ASKA Pharmaceutical扩大合作协议的领域和范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ae71223516e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESO

2020-05-29

hongbochen (审核中...)

前往app查看评论内容

#ESO#

J Endod：Resolvin E1通过Chemerin受体23抑制牙髓成纤维细胞活性改善牙髓炎

2019-08-10

hongbochen (审核中...)

前往app查看评论内容

#ESO#

NEJM：volanesorsen治疗乳糜微粒血症的关键研究结果

2019-08-10

hongbochen (审核中...)

前往app查看评论内容

#ESO#

Blood：Resolvin D4 (RvD4)可减轻病理性血栓形成

2019-07-18

hongbochen (审核中...)

前往app查看评论内容

#ESO#

ESOC2019丨混合性颅内出血的致残风险更高

2019-06-12

hongbochen (审核中...)

前往app查看评论内容

#ESO#

抗凝治疗脑出血怎么办？ESO 指南来支招

2019-05-25

hongbochen (审核中...)

前往app查看评论内容

#ESO#

2019 ESO指南：卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗

2019-05-08

hongbochen (审核中...)

前往app查看评论内容

#ESO#

2019 ESO/ESMINT指南：急性缺血性卒中机械血栓清除术

2019-03-13

hongbochen (审核中...)

前往app查看评论内容

#ESO#

【CSH重磅发布】伊布替尼一线治疗CLL研究RESONATE-2发布55个月随访结果

2018-10-31

hongbochen (审核中...)

前往app查看评论内容

#ESO#

Lancet：Resolute Onyx支架，效果和安全性不次于Orsiro药物洗脱支架的新型血管支架

2018-09-25

hongbochen (审核中...)

前往app查看评论内容

#ESO#

ESO-ESMO晚期乳腺癌国际共识指南更新了！看看不同类型乳腺癌怎么治？

2018-08-02

hongbochen (审核中...)

前往app查看评论内容

#ESO#

Sci Rep：给药途径对阴道生殖模型中mesoangioblasts干细胞命运的影响研究

2018-07-18

hongbochen (审核中...)

前往app查看评论内容

#ESO#

Hepatology：调节肠道胆汁酸/farnesoid X受体/成纤维细胞生长因子15轴，改善小鼠酒精性肝病

2018-06-30

hongbochen (审核中...)

前往app查看评论内容

#ESO#

【2018年EHA抢鲜报道】伊布替尼在CLL / SLL患者中的一线治疗：RESONATE-2研究的4年经验

2018-06-15

hongbochen (审核中...)

前往app查看评论内容

#ESO#

罗氏在“多重困难”后终止了olesoxime的开发

2018-06-03

hongbochen (审核中...)

前往app查看评论内容

#ESO#

CLIN CANCER RES：NY-ESO-1疫苗联合地西他滨可以诱导抗原特异性T淋巴细胞反应

2018-03-06

hongbochen (审核中...)

前往app查看评论内容

#ESO#

EUR J Cancer：ipilimumab在NY-ESO-1阳性黑色素瘤患者中的作用

2018-03-02

hongbochen (审核中...)

前往app查看评论内容

#ESO#

2017 EAN/ESO共识声明：卒中院前管理

2017-12-19

hongbochen (审核中...)

前往app查看评论内容

#ESO#

Kidney int：中美洲肾病（Mesoamerican nephropathy）知多少？

2017-12-16

hongbochen (审核中...)

前往app查看评论内容

#ESO#

【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案

2017-12-14

hongbochen (审核中...)

前往app查看评论内容

#ESO#

TesoRx Pharma和ASKA Pharmaceutical扩大合作协议的领域和范围

2017-12-07

科室
- - 订阅+
  - 更多科室
工具
服务